Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

All half-lives are wrong, but some half-lives are useful.

J G Wright1, A V Boddy

  • 1Cancer Research Unit, University of Newcastle, Medical School, Newcastle upon Tyne, England. Wright_James_G@lilly.com

Clinical Pharmacokinetics
|May 23, 2001
PubMed
Summary

Drug half-life and clearance are complementary pharmacokinetic parameters. Understanding their appropriate use, statistical reporting, and clinical context is crucial for accurate drug disposition interpretation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plantar flexion, dorsiflexion, range of movement and hindfoot deviation are important determinants of foot function in children.

Journal of children's orthopaedics·2019
Same author

Inter-rater reliability of the radiographic assessment of simple bone cysts.

Journal of children's orthopaedics·2019
Same author

Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.

British journal of clinical pharmacology·2018
Same author

A consensus exercise identifying priorities for research into clinical effectiveness among children's orthopaedic surgeons in the United Kingdom.

The bone & joint journal·2018
Same author

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).

Pediatric blood & cancer·2017
Same author

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Pediatric blood & cancer·2016

Area of Science:

  • Pharmacokinetics
  • Drug Metabolism and Disposition
  • Quantitative Pharmacology

Background:

  • Half-life is an intuitive pharmacokinetic parameter describing drug elimination over time.
  • It assumes a linear, first-order, time-invariant process, often a practical approximation.
  • Clearance offers complementary insights into drug elimination factors like enzyme inhibition or renal impairment.

Purpose of the Study:

  • To explore the complementary roles of drug half-life and clearance in pharmacokinetic modeling.
  • To highlight the importance of considering physiological processes and limitations of these parameters.
  • To emphasize the need for appropriate statistical reporting and clinical context in pharmacokinetic analysis.

Main Methods:

  • Conceptual analysis of pharmacokinetic parameters (half-life, clearance).

Related Experiment Videos

  • Discussion of linear pharmacokinetic models and their assumptions.
  • Consideration of multi-phase disposition and statistical estimation challenges.

    • Main Results:

    • Half-life and clearance are complementary, not alternative, parameters for linear pharmacokinetic models.
    • Accurate interpretation requires understanding underlying physiological processes and dose history.
    • Statistical aspects, including confidence intervals and population variability, are often overlooked in half-life estimation.

    Conclusions:

    • Pharmacokinetic parameters like half-life and clearance provide essential quantitative information but require careful interpretation.
    • Integrating dose history and pharmacodynamic end-points is vital for clinical relevance.
    • Improved statistical reporting of pharmacokinetic parameters is necessary for robust drug evaluation.